Greater

Vodafone Selects Dubber for UK & Europe Mobile Networks

Retrieved on: 
Thursday, December 1, 2022

A single view of conversations with end users across fixed and mobile networks will also deliver new personalised services and provide better customer experience.

Key Points: 
  • A single view of conversations with end users across fixed and mobile networks will also deliver new personalised services and provide better customer experience.
  • Work has commenced to migrate Vodafone's existing mobile recording customer base to an improved service on the Dubber platform and the companies will jointly explore new commercial opportunities to deliver additional Dubber services to Vodafone customers.
  • "Our initiative with Vodafone will deliver accretive revenue for Dubber and a larger addressable market.
  • Listed on the ASX, Dubber is the clear market leader in conversational intelligence and unified recording - embedded at the heart of over 175 service provider networks.

Vodafone Selects Dubber for UK & Europe Mobile Networks

Retrieved on: 
Thursday, December 1, 2022

A single view of conversations with end users across fixed and mobile networks will also deliver new personalised services and provide better customer experience.

Key Points: 
  • A single view of conversations with end users across fixed and mobile networks will also deliver new personalised services and provide better customer experience.
  • Work has commenced to migrate Vodafone's existing mobile recording customer base to an improved service on the Dubber platform and the companies will jointly explore new commercial opportunities to deliver additional Dubber services to Vodafone customers.
  • "Our initiative with Vodafone will deliver accretive revenue for Dubber and a larger addressable market.
  • Listed on the ASX, Dubber is the clear market leader in conversational intelligence and unified recording - embedded at the heart of over 175 service provider networks.

SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Monday, November 28, 2022

PARAMUS, N.J., Nov. 28, 2022 /PRNewswire/ -- SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, will present data on XCOPRI® (cenobamate tablets) CV, at the American Epilepsy Society (AES) Annual Meeting, to be held December 2 – 6, 2022 in Nashville, Tennessee.

Key Points: 
  • Cenobamateis an anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK life science.
  • DO NOT TAKE XCOPRI IF YOU:
    Are allergic to cenobamate or any of the other ingredients in XCOPRI.
  • Do not stop taking XCOPRI without first talking to your healthcare provider.Stopping XCOPRI suddenly can cause serious problems.
  • Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea.

2023 Global Insurance Symposium to Focus on ‘Thriving in a Changing World’

Retrieved on: 
Monday, November 14, 2022

We are honored to bring together the best and brightest insurance leaders from around the globe to the insurance powerhouse of DSM USA for the Global Insurance Symposium, said Jay Byers, President & CEO of the Greater Des Moines Partnership.

Key Points: 
  • We are honored to bring together the best and brightest insurance leaders from around the globe to the insurance powerhouse of DSM USA for the Global Insurance Symposium, said Jay Byers, President & CEO of the Greater Des Moines Partnership.
  • The three-day symposium will focus on the themes of thriving and changing as insurers are faced with an unprecedented scope of evolving challenges.
  • About the Global Insurance Symposium:
    Since its inception in 2014, the Global Insurance Symposium has hosted thousands of leading insurance and financial service professionals and regulatory authorities.
  • The Global Insurance Symposium is presented by the Greater Des Moines Partnership, the Iowa Insurance Division, the Iowa Economic Development Authority and members of the Iowa insurance industry.

Soundbite Medical Enters Into A License Agreement With VFLO Medical To Bring Its Products To Greater China

Retrieved on: 
Tuesday, November 15, 2022

Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that it has entered into an exclusive license agreement with VFLO Medical (VFLO).

Key Points: 
  • Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that it has entered into an exclusive license agreement with VFLO Medical (VFLO).
  • Pursuant to the agreement, Soundbite has granted VFLO an exclusive license for certain proprietary products including its SoundBite Crossing System and the Active Microcatheter System.
  • Under the Agreement, VFLO is entitled to manufacture, develop, and commercialize the products in the Greater China region, including Mainland China, Hong Kong, Macau, and Taiwan.
  • Soundbite is in return entitled to receive an upfront fee, subsequent milestone payments, plus royalties from sales of such products.

SK Biopharmaceuticals Named CES 2023 Innovation Awards Honoree

Retrieved on: 
Wednesday, November 16, 2022

PANGYO, South Korea, Nov. 16, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has been named a CES® 2023 Innovation Awards Honoree for outstanding design and engineering of two wearable devices – Zero GlassesTM and Zero WiredTM.

Key Points: 
  • PANGYO, South Korea, Nov. 16, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has been named a CES 2023 Innovation Awards Honoree for outstanding design and engineering of two wearable devices Zero GlassesTMand Zero WiredTM.
  • They are compatible with SK Biopharmaceuticals' mobile application named Zero AppTMthat can record and analyze bio-signal data in real time.
  • SK Biopharmaceuticals operates in the U.S. through SK Life Science, a subsidiary based in New Jersey.
  • SK Biopharmaceuticals will showcase the wearable devices and provide an on-site demonstration at CES 2023.

Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer

Retrieved on: 
Tuesday, November 15, 2022

In the TORCH study, 2 of the 3 patients with PRs were previously treated with a PD-1/PD-L1 antibody.

Key Points: 
  • In the TORCH study, 2 of the 3 patients with PRs were previously treated with a PD-1/PD-L1 antibody.
  • The updated and detailed study results of the TORCH and TORCH-2 will be presented at international scientific conferences in 2023.
  • As of the Oct 21, 2022 efficacy evaluation, 21 cervical cancer patients had been dosed with the ATG-008/toripalimab combination including 9 patients (42.9%) who were PD-L1 positive.
  • Initial results of the TORCH-2 study were presented at the 2022 American Society of Clinical Oncology (ASCO 2022) Annual Meeting.

EQS-News: init innovation in traffic systems SE: Success for digitalisation specialist from Karlsruhe

Retrieved on: 
Friday, November 11, 2022

init innovation in traffic systems SE: Success for digitalisation specialist from Karlsruhe

Key Points: 
  • init innovation in traffic systems SE: Success for digitalisation specialist from Karlsruhe
    The issuer is solely responsible for the content of this announcement.
  • One of the largest public transport companies in the USA - METRO Houston - continues to rely on the technology of Karlsruhe-based init innovation in traffic systems SE (ISINDE0005759807) for the modernisation of its fare management system.
  • Central intelligence of the account-based system is the background system MOBILEvario from init.
  • The order from METRO Houston is already the eighth major order for regional fare management systems that init has won in the USA in recent years.

Connect America Unveils Industry-First Enhancements to Connect America Home™ Platform

Retrieved on: 
Thursday, November 10, 2022

BALA CYNWYD, Pa., Nov. 10, 2022 /PRNewswire/ -- Connect America, the nationally recognized innovator in connective care technology to empower seniors and vulnerable populations to age gracefully in place, today announced several enhancements to its Connect America Home™ platform. This next-generation, AI-enabled digital health and safety platform provides secure, non-intrusive, continuous monitoring with emergency and non-emergency support to help everyone live safely, independently, and well at home.

Key Points: 
  • Enhanced Mobility Reporting and Safety: Connect America also announced today that its Connect America Home platform has been enhanced with the ability to capture movement and activity, such as daily steps, through its member-worn Personal Emergency Response Service (PERS) device.
  • SDoH Support: Additionally, Connect America is using the Uber Health platform to provide Non-Emergency Medical Transportation to patients who can request a ride by contacting a Connect America call center.
  • "We are excited about our strategic partnership with Connect America as this supports this level of health data sharing with focus on the home care delivery model."
  • With improved outcomes, reduced hospitalizations and lower care costs, patients and their care circles have peace of mind knowing Connect America is how health and home connect.

Baozun Acquires Gap Greater China and Establishes Brand Management as a New Business Line

Retrieved on: 
Tuesday, November 8, 2022

Gap Greater China is wholly owned by Gap Inc. (Gap), the largest American specialty apparel company offering iconic comfort-casual wear, accessories, and personal care products for men, women, and children.

Key Points: 
  • Gap Greater China is wholly owned by Gap Inc. (Gap), the largest American specialty apparel company offering iconic comfort-casual wear, accessories, and personal care products for men, women, and children.
  • Since its first China store in 2010, Gap Greater China has achieved robust expansion throughout Greater China, amassing broad brand awareness with close to 30 million loyalty members in the region.
  • Since December 2018, the Company has served Gap Greater China as its e-commerce service partner, and successfully enabled Gap Greater China to expand its e-commerce business in Greater China, delivering solid growth.
  • The substantial size and scope of Gap Greater China make this acquisition a significant step in developing BBM.